LMR Partners’s Passage Bio PASG Stock Holding History

LMR Partners’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-661	Closed	-$17K	–	1226
2022 Q3	$17K	Hold	661	–	–	﹤0.01%	1175
2022 Q2	$31K	Buy	+661	New	+$30.9K	﹤0.01%	1203

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

LMR Partners's PASG Position: Q4 2022 in Review

LMR Partners sold out of Passage Bio (PASG) in Q4 2022, closing a stake of 661 shares — an estimated $17K sold.

LMR Partners first reported a position in PASG in Q2 2022 and held it in 2 quarters. The position peaked at $31K in Q2 2022. 67 funds tracked by Wall St. Rank hold PASG as of Q4 2022.

LMR Partners reported no remaining Passage Bio position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 661 Passage Bio shares in Q4 2022, an estimated $17K.
LMR Partners first reported a position in Passage Bio in Q2 2022 and held it in 2 quarters.
LMR Partners's Passage Bio position peaked at $31K in Q2 2022.
67 funds tracked by Wall St. Rank held Passage Bio as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.